Therapeutic Potential of a Vasopressin V2 Receptor Antagonist for Calcium Channel Blocker-Associated Edema with Vasospastic Angina

Calcium channel blocker- (CCB-) associated peripheral edema does not resolve without CCB discontinuation or dose reduction. However, renin–angiotensin system (RAS) inhibitors have been reported to be effective for CCB-associated edema. We report a case of vasospastic angina with refractory CCB-assoc...

Full description

Saved in:
Bibliographic Details
Main Authors: Kojiro Toda, Masashi Fujino, Kota Murai, Teruo Noguchi
Format: Article
Language:English
Published: Wiley 2022-01-01
Series:Case Reports in Cardiology
Online Access:http://dx.doi.org/10.1155/2022/9550006
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850176701438361600
author Kojiro Toda
Masashi Fujino
Kota Murai
Teruo Noguchi
author_facet Kojiro Toda
Masashi Fujino
Kota Murai
Teruo Noguchi
author_sort Kojiro Toda
collection DOAJ
description Calcium channel blocker- (CCB-) associated peripheral edema does not resolve without CCB discontinuation or dose reduction. However, renin–angiotensin system (RAS) inhibitors have been reported to be effective for CCB-associated edema. We report a case of vasospastic angina with refractory CCB-associated edema. A 78-year-old man had refractory edema induced by a CCB. It was successfully treated with tolvaptan, an active vasopressin V2 receptor antagonist. The aim of this case report is to understand the mechanism and treatment of CCB-associated peripheral edema and how tolvaptan affects peripheral edema.
format Article
id doaj-art-bd5f6ebdf9cf4456b638c8a46dd0860a
institution OA Journals
issn 2090-6412
language English
publishDate 2022-01-01
publisher Wiley
record_format Article
series Case Reports in Cardiology
spelling doaj-art-bd5f6ebdf9cf4456b638c8a46dd0860a2025-08-20T02:19:12ZengWileyCase Reports in Cardiology2090-64122022-01-01202210.1155/2022/9550006Therapeutic Potential of a Vasopressin V2 Receptor Antagonist for Calcium Channel Blocker-Associated Edema with Vasospastic AnginaKojiro Toda0Masashi Fujino1Kota Murai2Teruo Noguchi3Department of Cardiovascular MedicineDepartment of Cardiovascular MedicineDepartment of Cardiovascular MedicineDepartment of Cardiovascular MedicineCalcium channel blocker- (CCB-) associated peripheral edema does not resolve without CCB discontinuation or dose reduction. However, renin–angiotensin system (RAS) inhibitors have been reported to be effective for CCB-associated edema. We report a case of vasospastic angina with refractory CCB-associated edema. A 78-year-old man had refractory edema induced by a CCB. It was successfully treated with tolvaptan, an active vasopressin V2 receptor antagonist. The aim of this case report is to understand the mechanism and treatment of CCB-associated peripheral edema and how tolvaptan affects peripheral edema.http://dx.doi.org/10.1155/2022/9550006
spellingShingle Kojiro Toda
Masashi Fujino
Kota Murai
Teruo Noguchi
Therapeutic Potential of a Vasopressin V2 Receptor Antagonist for Calcium Channel Blocker-Associated Edema with Vasospastic Angina
Case Reports in Cardiology
title Therapeutic Potential of a Vasopressin V2 Receptor Antagonist for Calcium Channel Blocker-Associated Edema with Vasospastic Angina
title_full Therapeutic Potential of a Vasopressin V2 Receptor Antagonist for Calcium Channel Blocker-Associated Edema with Vasospastic Angina
title_fullStr Therapeutic Potential of a Vasopressin V2 Receptor Antagonist for Calcium Channel Blocker-Associated Edema with Vasospastic Angina
title_full_unstemmed Therapeutic Potential of a Vasopressin V2 Receptor Antagonist for Calcium Channel Blocker-Associated Edema with Vasospastic Angina
title_short Therapeutic Potential of a Vasopressin V2 Receptor Antagonist for Calcium Channel Blocker-Associated Edema with Vasospastic Angina
title_sort therapeutic potential of a vasopressin v2 receptor antagonist for calcium channel blocker associated edema with vasospastic angina
url http://dx.doi.org/10.1155/2022/9550006
work_keys_str_mv AT kojirotoda therapeuticpotentialofavasopressinv2receptorantagonistforcalciumchannelblockerassociatededemawithvasospasticangina
AT masashifujino therapeuticpotentialofavasopressinv2receptorantagonistforcalciumchannelblockerassociatededemawithvasospasticangina
AT kotamurai therapeuticpotentialofavasopressinv2receptorantagonistforcalciumchannelblockerassociatededemawithvasospasticangina
AT teruonoguchi therapeuticpotentialofavasopressinv2receptorantagonistforcalciumchannelblockerassociatededemawithvasospasticangina